Efficacy of Terpenoid in Attenuating Aortic Atherosclerosis in Apolipoprotein-E Deficient Mice: A Meta-Analysis of Animal Studies

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2019 Aug 9

PMID 31392210

Citations 4

Authors

Han Liu

Yang Zhang

Siqiao Sun

Shuai Wang

Affiliations

Soon will be listed here.

Abstract

Background: The apolipoprotein E knockout (ApoE -/-) mouse model is well established for the study of terpenoids in the prevention of atherosclerosis. Studies investigating the clinical benefit of terpenoids in humans are scarce. This systematic review and meta-analysis evaluated the effects of terpenoid administration on atherosclerotic lesion area in ApoE -/- mice.

Methods: A comprehensive literature search using PubMed, Embase, and the Cochrane Library databases was performed to identify studies that assessed the effects of terpenoids on atherosclerosis in ApoE -/- mice. The primary outcome was atherosclerotic lesion area, and study quality was estimated using SYRCLE's risk of bias tool.

Results: The meta-analysis included 25 studies. Overall, terpenoids significantly reduced atherosclerotic lesion area when compared to vehicle control (<0.00001; SMD: -0.55; 95% CI: -0.72, -0.39). In terpenoid type and dose subgroup analyses, sesquiterpenoid (=0.002; SMD -0.93; 95% CI: -1.52, -0.34), diterpenoid (=0.01; SMD: -0.30; 95% CI: -0.54, -0.06), triterpenoid (<0.00001; SMD: -0.66; 95% CI: -0.94, -0.39), tetraterpenoid (<0.0001; SMD: -1.81; 95% CI: -2.70, -0.91), low dose (=0.0001; SMD: -0.51; 95% CI: -0.76, -0.25), medium dose (0.0001; SMD: -0.48; 95% CI: -0.72, -0.24), and high dose (=0.002; SMD: -1.07; 95% CI: -1.74, -0.40) significantly decreased atherosclerotic lesion area when compared to vehicle control. PROSPERO register number is CRD42019121176.

Conclusion: Sesquiterpenoid, diterpenoid, triterpenoid, and tetraterpenoid have potential as antiatherosclerotic agents with a wide range of doses. This systematic review provides a reference for research programs aimed at the development of terpenoid-based clinical drugs.

Citing Articles

Improving Genetic Association Studies with a Novel Methodology that Unveils the Hidden Complexity of All-Cause Heart Failure.

Gregg J, Himes B, Asselbergs F, Moore J medRxiv. 2023; .

PMID: 37577697 PMC: 10418568. DOI: 10.1101/2023.08.02.23293567.

Efficacy of terpenoids in attenuating pulmonary edema in acute lung injury: A meta-analysis of animal studies.

Wang S, Luo S, Jie J, Li D, Liu H, Song L Front Pharmacol. 2022; 13:946554.

PMID: 36034851 PMC: 9401633. DOI: 10.3389/fphar.2022.946554.

Effects of toxic apolipoprotein E fragments on Tau phosphorylation and cognitive impairment in neonatal mice under sevoflurane anesthesia.

Yu Y, Yang M, Zhuang X, Pan J, Zhao Y, Yu Y Brain Behav. 2022; 12(8):e2702.

PMID: 35810473 PMC: 9392520. DOI: 10.1002/brb3.2702.

[Metabolomic changes of neonatal sepsis: an exploratory clinical study].

Tong P, Huang F, Xu J, Wu Z, Hu X, Ling M Zhongguo Dang Dai Er Ke Za Zhi. 2022; 24(6):675-680.

PMID: 35762435 PMC: 9250401. DOI: 10.7499/j.issn.1008-8830.2112020.

References

Dwyer J, Navab M, Dwyer K, Hassan K, Sun P, Shircore A . Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation. 2001; 103(24):2922-7. DOI: 10.1161/01.cir.103.24.2922. View

Steffens S, Veillard N, Arnaud C, Pelli G, Burger F, Staub C . Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005; 434(7034):782-6. DOI: 10.1038/nature03389. View

Huang T, Razmovski-Naumovski V, Salam N, Duke R, Tran V, Duke C . A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem Pharmacol. 2005; 70(9):1298-308. DOI: 10.1016/j.bcp.2005.07.033. View

Takeda N, Manabe I, Shindo T, Iwata H, Iimuro S, Kagechika H . Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol. 2006; 26(5):1177-83. DOI: 10.1161/01.ATV.0000214296.94849.1c. View

Lopez-Franco O, Hernandez-Vargas P, Ortiz-Munoz G, Sanjuan G, Suzuki Y, Ortega L . Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26(8):1864-70. DOI: 10.1161/01.ATV.0000229659.94020.53. View

Zadelaar S, Kleemann R, Verschuren L, de Vries-van der Weij J, van der Hoorn J, Princen H . Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007; 27(8):1706-21. DOI: 10.1161/ATVBAHA.107.142570. View

Liu G, Wang B, Zhang J, Jiang H, Liu F . Total panax notoginsenosides prevent atherosclerosis in apolipoprotein E-knockout mice: Role of downregulation of CD40 and MMP-9 expression. J Ethnopharmacol. 2009; 126(2):350-4. DOI: 10.1016/j.jep.2009.08.014. View

Victor V, Rocha M, Sola E, Banuls C, Garcia-Malpartida K, Hernandez-Mijares A . Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des. 2009; 15(26):2988-3002. DOI: 10.2174/138161209789058093. View

Guri A, Misyak S, Hontecillas R, Hasty A, Liu D, Si H . Abscisic acid ameliorates atherosclerosis by suppressing macrophage and CD4+ T cell recruitment into the aortic wall. J Nutr Biochem. 2010; 21(12):1178-85. PMC: 2891372. DOI: 10.1016/j.jnutbio.2009.10.003. View

10.

Tang F, Cao Y, Wang T, Wang L, Guo J, Zhou X . Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol. 2010; 650(1):275-84. DOI: 10.1016/j.ejphar.2010.07.038. View

11.

Li J, Xie Z, Tang Y, Zhou J, Guan Y . Ginsenoside-Rd, a purified component from panax notoginseng saponins, prevents atherosclerosis in apoE knockout mice. Eur J Pharmacol. 2010; 652(1-3):104-10. DOI: 10.1016/j.ejphar.2010.11.017. View

12.

Koba S, Hirano T . [Dyslipidemia and atherosclerosis]. Nihon Rinsho. 2011; 69(1):138-43. View

13.

Logue J, Murray H, Welsh P, Shepherd J, Packard C, MacFarlane P . Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart. 2011; 97(7):564-8. DOI: 10.1136/hrt.2010.211201. View

14.

Katsumata A, Kimura M, Saigo H, Aburaya K, Nakano M, Ikeda T . Changes in esculeoside A content in different regions of the tomato fruit during maturation and heat processing. J Agric Food Chem. 2011; 59(8):4104-10. DOI: 10.1021/jf104025p. View

15.

Messner B, Zeller I, Ploner C, Frotschnig S, Ringer T, Steinacher-Nigisch A . Ursolic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis. 2011; 219(2):402-8. DOI: 10.1016/j.atherosclerosis.2011.05.025. View

16.

Yang Z, Liu J, Ge J, Chen L, Zhao Z, Yang W . Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J. 2011; 33(2):213-20. DOI: 10.1093/eurheartj/ehr205. View

17.

Xu S, Little P, Lan T, Huang Y, Le K, Wu X . Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys. 2011; 515(1-2):72-9. DOI: 10.1016/j.abb.2011.08.006. View

18.

Buus N, Hansson N, Rodriguez-Rodriguez R, Stankevicius E, Andersen M, Simonsen U . Antiatherogenic effects of oleanolic acid in apolipoprotein E knockout mice. Eur J Pharmacol. 2011; 670(2-3):519-26. DOI: 10.1016/j.ejphar.2011.09.037. View

19.

Jawien J . The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis. Curr Pharm Biotechnol. 2012; 13(13):2435-9. View

20.

Chen H, Yang J, Zhang Q, Chen L, Wang Q . Corosolic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice by regulating the nuclear factor-κB signaling pathway and inhibiting monocyte chemoattractant protein-1 expression. Circ J. 2012; 76(4):995-1003. DOI: 10.1253/circj.cj-11-0344. View